Literature DB >> 17224157

Differential effects of AT1 receptor and Ca2+ channel blockade on atherosclerosis, inflammatory gene expression, and production of reactive oxygen species.

Derek E Doran1, Daiana Weiss, Yong Zhang, Kathy K Griendling, W Robert Taylor.   

Abstract

Angiotensin II receptor blockade has been shown to inhibit atherosclerosis in several different animal models. We sought to determine if this effect was the result of blood pressure reduction per se or a result of the anti-inflammatory effects of receptor blockade. ApoE-deficient mice were fed a high fat diet and treated with either an angiotensin II receptor antagonist, candesartan (0.5 mg/kg/day, s.c.) or a calcium channel blocker, amlodipine (7.5 mg/kg/day, mixed with food). Atherosclerotic lesion area, aortic inflammatory gene expression as well as aortic H2O2 and superoxide production were assayed. We found that candesartan but not amlodipine treatment dramatically attenuated the development of atherosclerosis despite a similar reduction in blood pressure. Similarly, candesartan treatment inhibited aortic expression of inflammatory genes and production of reactive oxygen species, effects not seen with amlodipine. These data demonstrate that angiotensin II receptor blockade inhibits atherosclerosis by reducing vascular oxidative stress and inflammatory gene production independent of blood pressure reduction.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17224157      PMCID: PMC2141541          DOI: 10.1016/j.atherosclerosis.2006.11.030

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  56 in total

1.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

2.  Acute and chronic angiotensin-1 receptor antagonism reverses endothelial dysfunction in atherosclerosis.

Authors:  A Prasad; T Tupas-Habib; W H Schenke; R Mincemoyer; J A Panza; M A Waclawin; S Ellahham; A A Quyyumi
Journal:  Circulation       Date:  2000-05-23       Impact factor: 29.690

3.  Angiotensin II-induced hypertension accelerates the development of atherosclerosis in apoE-deficient mice.

Authors:  D Weiss; J J Kools; W R Taylor
Journal:  Circulation       Date:  2001-01-23       Impact factor: 29.690

4.  Theodore Cooper Lecture: Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis.

Authors:  V J Dzau
Journal:  Hypertension       Date:  2001-04       Impact factor: 10.190

5.  Matrix metalloproteinase-9 and tissue inhibitor metalloproteinase-1 levels in essential hypertension. Relationship to left ventricular mass and anti-hypertensive therapy.

Authors:  F L Li-Saw-Hee; E Edmunds; A D Blann; D G Beevers; G Y Lip
Journal:  Int J Cardiol       Date:  2000-08       Impact factor: 4.164

6.  Chronic angiotensin II infusion promotes atherogenesis in low density lipoprotein receptor -/- mice.

Authors:  A Daugherty; L Cassis
Journal:  Ann N Y Acad Sci       Date:  1999-11-18       Impact factor: 5.691

7.  Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice.

Authors:  A Daugherty; M W Manning; L A Cassis
Journal:  J Clin Invest       Date:  2000-06       Impact factor: 14.808

Review 8.  Reactive oxygen species as mediators of angiotensin II signaling.

Authors:  K K Griendling; M Ushio-Fukai
Journal:  Regul Pept       Date:  2000-07-28

9.  The angiotensin-converting enzyme inhibitor, fosinopril, and the angiotensin II receptor antagonist, losartan, inhibit LDL oxidation and attenuate atherosclerosis independent of lowering blood pressure in apolipoprotein E deficient mice.

Authors:  T Hayek; J Attias; R Coleman; S Brodsky; J Smith; J L Breslow; S Keidar
Journal:  Cardiovasc Res       Date:  1999-12       Impact factor: 10.787

10.  Molecular dissection of angiotensin II-activated human LOX-1 promoter.

Authors:  Jiawei Chen; Yong Liu; Hongmei Liu; Paul L Hermonat; Jawahar L Mehta
Journal:  Arterioscler Thromb Vasc Biol       Date:  2006-02-16       Impact factor: 8.311

View more
  19 in total

1.  Comparative effects of different modes of renin angiotensin system inhibition on hypercholesterolaemia-induced atherosclerosis.

Authors:  Hong Lu; Anju Balakrishnan; Deborah A Howatt; Congqing Wu; Richard Charnigo; Gene Liau; Lisa A Cassis; Alan Daugherty
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

2.  Differential effects of dietary sodium intake on blood pressure and atherosclerosis in hypercholesterolemic mice.

Authors:  Hong Lu; Congqing Wu; Deborah A Howatt; Anju Balakrishnan; Richard J Charnigo; Lisa A Cassis; Alan Daugherty
Journal:  J Nutr Biochem       Date:  2012-06-15       Impact factor: 6.048

3.  Chronic treatment with angiotensin-(1-7) improves renal endothelial dysfunction in apolipoproteinE-deficient mice.

Authors:  J Stegbauer; S A Potthoff; I Quack; E Mergia; T Clasen; S Friedrich; O Vonend; M Woznowski; E Königshausen; L Sellin; L C Rump
Journal:  Br J Pharmacol       Date:  2011-07       Impact factor: 8.739

4.  Cross talk between the renin-angiotensin-aldosterone system and vitamin D-FGF-23-klotho in chronic kidney disease.

Authors:  Martin H de Borst; Marc G Vervloet; Piet M ter Wee; Gerjan Navis
Journal:  J Am Soc Nephrol       Date:  2011-08-18       Impact factor: 10.121

5.  Angiotensin-converting enzyme 2 deficiency in whole body or bone marrow-derived cells increases atherosclerosis in low-density lipoprotein receptor-/- mice.

Authors:  Sean E Thatcher; Xuan Zhang; Deborah A Howatt; Hong Lu; Susan B Gurley; Alan Daugherty; Lisa A Cassis
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-01-20       Impact factor: 8.311

Review 6.  Do we need more than just powerful blood pressure reductions? New paradigms in end-organ protection.

Authors:  Domenico Galzerano; Cristina Capogrosso; Sara Di Michele; Emanuele Bobbio; Paola Paparello; Carlo Gaudio
Journal:  Vasc Health Risk Manag       Date:  2010-08-09

7.  Attenuation of inflammation and expansive remodeling by Valsartan alone or in combination with Simvastatin in high-risk coronary atherosclerotic plaques.

Authors:  Yiannis S Chatzizisis; Michael Jonas; Roy Beigel; Ahmet U Coskun; Aaron B Baker; Benjamin V Stone; Charles Maynard; Ross G Gerrity; William Daley; Elazer R Edelman; Charles L Feldman; Peter H Stone
Journal:  Atherosclerosis       Date:  2008-08-05       Impact factor: 5.162

8.  Renin inhibition reduces hypercholesterolemia-induced atherosclerosis in mice.

Authors:  Hong Lu; Debra L Rateri; David L Feldman; Richard J Charnigo; Akiyoshi Fukamizu; Junji Ishida; Elizabeth G Oesterling; Lisa A Cassis; Alan Daugherty
Journal:  J Clin Invest       Date:  2008-03       Impact factor: 14.808

9.  Effects of angiotensin II AT₁-receptor blockade on high fat diet-induced vascular oxidative stress and endothelial dysfunction in Dahl salt-sensitive rats.

Authors:  Shinji Kosaka; Nicolas Pelisch; Matlubur Rahman; Daisuke Nakano; Hirofumi Hitomi; Hiroyuki Kobori; Noriyasu Fukuoka; Hideki Kobara; Hirohito Mori; Tsutomu Masaki; Ludek Cervenka; Yasuo Matsumura; Hitoshi Houchi; Akira Nishiyama
Journal:  J Pharmacol Sci       Date:  2013-01-22       Impact factor: 3.337

10.  Hypertension and decreased aortic compliance due to reduced elastin amounts do not increase atherosclerotic plaque accumulation in Ldlr-/- mice.

Authors:  Justine A Maedeker; Kellie V Stoka; Siddharth A Bhayani; William S Gardner; Lisa Bennett; Jesse D Procknow; Marius C Staiculescu; Tezin A Walji; Clarissa S Craft; Jessica E Wagenseil
Journal:  Atherosclerosis       Date:  2016-03-21       Impact factor: 5.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.